BIOLINERX | Investor Information | 2015 Press releases

2015 Press releases

Receive e-mail alerts |

Rss feeds

Keyword search

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

Date	Title
12/14/15	BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
12/03/15	BioLineRx Establishes Oncology Scientific Advisory Board
11/25/15	BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
11/24/15	BioLineRx to Present at the LD Micro Main Event
11/23/15	BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
11/16/15	BioLineRx Reports Third Quarter 2015 Financial Results
11/09/15	BioLineRx to Report Third Quarter 2015 Results on November 16, 2015
11/05/15	BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML
09/10/15	BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
09/09/15	BioLineRx’s Novel Treatment for Non-Surgical Removal of Skin Lesions Submitted for CE Mark Registration
09/03/15	BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York
08/20/15	BioLineRx Reports Second Quarter 2015 Financial Results
08/17/15	BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment
08/13/15	BioLineRx to Report Second Quarter 2015 Results on August 20, 2015
07/27/15	BioLineRx Announces Top-Line Results from Bellerophon’s PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)
06/17/15	BioLineRx to Present Successful Results of Phase 1/2 Study for Novel Celiac Treatment at International Celiac Disease Symposium
06/16/15	BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
06/15/15	BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference
06/03/15	Research Underlying BioLineRx’s Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award
06/01/15	BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions
05/27/15	BioLineRx to Present Positive Safety and Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at the European Hematology Annual Congress
05/18/15	BioLineRx Reports First Quarter 2015 Financial Results
05/11/15	BioLineRx to Report First Quarter 2015 Results on May 18, 2015
05/04/15	BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia
03/25/15	BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment
03/23/15	BioLineRx Reports Year End 2014 Financial Results
03/17/15	BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015
03/11/15	BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
03/11/15	BioLineRx’s Treatment for Type 1 Diabetes Effective in Preclinical Trials
03/06/15	BioLineRx to Present at the Annual Roth Conference in California
03/06/15	BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares
03/05/15	BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
03/02/15	BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment
02/03/15	BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10
01/14/15	BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
01/06/15	BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment
01/06/15	BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco